Table 1.
Baseline demographics and disease characteristics.
| Disease characteristics | Number (N = 10) |
|---|---|
| Age, years old | |
| Median | 64.5 |
| Range | 48–80 |
| ECOG status | |
| 0 | 3 |
| 1 | 6 |
| 2 | 0 |
| 3 | 1 |
| Ethnicity | |
| Asian | 4 |
| Caribbean | 3 |
| Latino | 2 |
| Russian | 1 |
| FIGO stage at initial diagnosis | |
| I | 1 |
| II | 5 |
| III | 3 |
| IV | 1 |
| Histology | |
| Squamous cell | 10 |
| Adenocarcinoma | 0 |
| Small cell | 1 (transformed from squamous cell) |
| Previous treatment with platinum | 10 |
| Chemoradiation primary treatment | 7 |
| Chemoradiation adjuvant treatment | 2 |
| Chemotherapy for metastatic disease | |
| Using platinum | 8 |
| Using bevacizumab | 6 |
| No of previous lines of therapy for recurrence/metastasis before IO | |
| 0 | 2 |
| 1 | 5 |
| 2 | 1 |
| 3 | 2 |
| Sites of metastatic lesions | |
| LN only | 3 |
| Pelvic organs | 2 |
| Visceral metastases | 2 |
| Other | 3 |
| Platinum sensitivity | |
| Sensitive | 5 |
| Resistant | 5 |
| Immunotherapy received | |
| Pembrolizumab | 9 |
| Nivolumab | 1 |
| PD-L1 combined positive score (CPS) | |
| 0 | 1 |
| 1–9 | 3 |
| 10–100 | 6 |
| Microsatellite status (MS) | |
| MS stable | 7 |
| MS instability | 0 |
| Not assessed | 3 |
| Tumor mutation burden (TMB)* | |
| TMB <10 | 3 |
| TMB ≥ 10 mut/Mb | 4 |
| P16 status | |
| Positive | 6 |
| Negative | 1 |
| Not assessed | 3 |
*
Seven of the patients had tumor mutation burden measured.